Pegylated recombinant human hyaluronidase - Halozyme

Drug Profile

Pegylated recombinant human hyaluronidase - Halozyme

Alternative Names: PEG PH20; PEG rHuPH-20; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Developer Eisai Co Ltd; Halozyme Therapeutics; Scripps Health; University of California at San Francisco
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Gastric cancer

Most Recent Events

  • 04 Apr 2017 9213879 - added development line for gastric cancer as per the MR; moreover, a phase I/II trial is planned for the indication in the second half of 2017 by Genentech and Halozyme
  • 03 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual meeting of the American Association of Cancer Research (AACR-2017)
  • 30 Mar 2017 Southwest Oncology Group in collaboration with Halozyme Therapeutics and National Cancer Institute suspends enrolment in a phase Ib/II trial for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top